Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80% of all lung cancers. While NF-kappa-B-activating protein-like (NKAPL) has been positively correlated with prognosis in various cancer types, its specific role in the progression of NSCLC remains undetermined.
This research published in the
Genes & Diseases journal by a team from Chongqing Medical University, Suining Central Hospital, Chongqing University and Sichuan University investigates the potential mechanisms underlying NSCLC growth.
Using AI-based machine learning, the team found that NKAPL had a high importance score of 0.9027 in patients with NSCLC. The expression of NKAPL was examined in NSCLC cell lines and matched primary NSCLC tissues. The results revealed significant downregulation of NKAPL in NSCLC, which correlated with clinicopathological parameters. Notably, methylation-specific PCR analysis of primary NSCLC tissues revealed that 99.38% of NKAPL promoters were hypermethylated. These findings confirm that NKAPL downregulation was due to promoter methylation, which was associated with poor prognosis in NSCLC patients.
Subsequent
in vitro experiments demonstrated that increased NKAPL expression in NSCLC cell lines inhibited cell proliferation, decreased migration and invasion, induced cell cycle arrest at the G2/M phase, and promoted apoptosis.
In vivo, NKAPL overexpression substantially inhibited tumor growth and metastasis in metastatic mouse models, firmly establishing its role as a tumor suppressor in NSCLC.
Bioinformatics analysis revealed that the tripartite motif-containing 21 (TRIM21) protein is strongly correlated with NKAPL expression. Furthermore, NKAPL overexpression prolonged the half-life of TRIM21, indicating that NKAPL enhances TRIM21 expression by stabilizing the protein. Moreover, knockdown of TRIM21 induced partial restoration of p65 phosphorylation by NKAPL overexpression, highlighting NKAPL’s ability to suppress the NF-κB signaling pathway via TRIM21. Interestingly, TRIM21 knockdown reversed the inhibitory effect of NKAPL on NSCLC cells.
In conclusion, this study reveals that low expression of NKAPL, primarily due to hypermethylation, serves as a potential indicator of poor prognosis in NSCLC. Overall, the findings of this research could pave the way for the development of NKAPL methylation inhibitors and NKAPL-targeted delivery systems as part of combination therapies for NSCLC.
Reference
Title of Original Paper: NKAPL suppresses NSCLC progression by enhancing the protein stability of TRIM21 and further inhibiting the NF-κB signaling pathway
Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.
DOI: https://doi.org/10.1016/j.gendis.2025.101598
Funding Information:
National Natural Science Foundation of China (No. 82172619)
Natural Science Foundation of Chongqing, China (No. CSTC2021jscx-gksb-N0023, CSTB2022NSCQ-M SX0063, CSTB2023NSCQ-MSX0386)
Medical and Industrial Integration Project (No. 2022CDJYGRH-002)
Sichuan Science and Technology Program, China (No. 2025ZNSFSC1926)
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 8.4 |
Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to
Genes & Disease may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (
https://x.com/GenesNDiseases)